Novartis Institutes for Biomedical Research on a number of venture capital transactions.
OncoVerity, a pioneer in applying advanced bioinformatics to drug development, on the closing of a Series A extension financing led by existing investors, argenx and RefinedScience.
Eurazeo, Bpifrance and Accel on their Series G investment in Doctolib, which, with its €5.8bn valuation, became the most valuable unicorn in the French tech sector at the time of closing.
Rice University on its launch of RBL LLC, a biotech venture creation studio developed out of the Rice Biotech Launch Pad, the university’s biotech innovation accelerator.
CatalYm GmbH, a Munich-based life sciences company, on a significant US$150m venture capital funding round.
